• Je něco špatně v tomto záznamu ?

Trop2: Jack of All Trades, Master of None

S. Lenárt, P. Lenárt, J. Šmarda, J. Remšík, K. Souček, P. Beneš,

. 2020 ; 12 (11) : . [pub] 20201111

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001784

Grantová podpora
NV18-07-00073, 17-28518A, and 18-08-00245 Ministerstvo Zdravotnictví Ceské Republiky
National Program of Sustainability II LQ1605 Ministerstvo Školství, Mládeže a Tělovýchovy
MUNI/A/1127/2019 Grant Agency of the Masaryk University
CETOCOEN PLUS (CZ.02.1.01/0.0/0.0/15_003/0000469) Ministerstvo Školství, Mládeže a Tělovýchovy
Support Grant P30 CA008748 Memorial Sloan-Kettering Cancer Center
CETOCOEN EXCELLENCE Teaming 2 (02.1.01/0.0/0.0/18_046/0015975) Horizon2020 (857560) a Ministerstvo Školství, Mládeže a Tělovýchovy

Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001784
003      
CZ-PrNML
005      
20210126092749.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12113328 $2 doi
035    __
$a (PubMed)33187148
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lenárt, Sára $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
245    10
$a Trop2: Jack of All Trades, Master of None. / $c S. Lenárt, P. Lenárt, J. Šmarda, J. Remšík, K. Souček, P. Beneš,
520    9_
$a Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Lenárt, Peter $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic. Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Šmarda, Jan $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic.
700    1_
$a Remšík, Ján $u Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
700    1_
$a Souček, Karel $u Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, 612 65 Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic.
700    1_
$a Beneš, Petr $u Department of Experimental Biology, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic. Center of Biomolecular and Cellular Engineering, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 11 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33187148 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092745 $b ABA008
999    __
$a ind $b bmc $g 1614013 $s 1122068
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 11 $e 20201111 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NV18-07-00073, 17-28518A, and 18-08-00245 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a National Program of Sustainability II LQ1605 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a MUNI/A/1127/2019 $p Grant Agency of the Masaryk University
GRA    __
$a CETOCOEN PLUS (CZ.02.1.01/0.0/0.0/15_003/0000469) $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a Support Grant P30 CA008748 $p Memorial Sloan-Kettering Cancer Center
GRA    __
$a CETOCOEN EXCELLENCE Teaming 2 (02.1.01/0.0/0.0/18_046/0015975) $p Horizon2020 (857560) a Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace